📌 Key Takeaways
- Topic: Silicon Dioxide Chemical Properties: Reactivity, Stability and Key Reactions
- Keywords: spherical silica for semiconductor packaging
- Published: 2026-11-20 10:15:43
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
What Is Hydrophilic Fumed Silica? Properties, BET Grades and Typical Uses
- Fumed Silica 380 m²/g: Properties, Thickening Performance and Applications
- Amin, M. U. et al. Enhanced efficacy and drug delivery with lipid coated mesoporous silica nanoparticles in cancer therapy. Eur. J. Pharm. Biopharm. 165, 31-40 (2021). Piece CAS PubMed Google Scholar
- Silica Exposure Limits: OSHA, ACGIH and EU Limits Compared
- Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.
- What Is Silica Aerogel? Structure, Thermal Performance and Insulation Applications
- What Is Spherical Silica? Benefits, Specifications and Uses in Semiconductor Packaging
What Is Mesoporous Silica? Structure, Pore Size and Applications in Drug Delivery and Catalysis
What is silica (SiO₂)?
silica particle size
What is the difference between fumed silica and precipitated silica?
silica mesh size
What drives silica raw material prices?
silica factory Secondly, it is needed to construct simple but efficient MSNs-based nanoplatforms. The abundant traits of MSNs have led to their vast exploitation as multifunctional nanocarriers, and this may be accompanied by the introduction of two or more elements into MSNs. Although these multifunctional nanoplatforms have proven to be really effective in numerous papers, the complexity of these platforms does not appear to be friendly to the scale-up preparation and clinical translation. On the one hand, it is well known that the laboratory-level synthesis methods of MSN are very different from those used for industrial scale-up production required for clinical screening and use. The reproducibility and batch stability of nanoformulations are always an important component to consider in industrial scale-up production, and in this process, simplifying the production steps is the key to promote the industrial scale-up production. Nonetheless, the complex MSNs-based nanoplatforms call for higher nanoformulation preparation technologies and more stringent storage methods, which often call for more time, effort, and economic investments. On the other hand, the multiple components may introduce more unsafe factors, it appears to be an enormous challenge at this stage to systematically reveal the toxicity mechanisms of these different components when we still do not entirely understand the toxicity mechanisms of MSNs. Hence, it is advocated to slim down the MSNs-based platform as much as possible while meeting the clinical requirements.
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.